News from isis pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 16, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Initiates Phase 1/2 Study of ISIS-DMPK Rx in Patients With Myotonic Dystrophy Type 1

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a study for ISIS-DMPKRx in patients with Myotonic Dystrophy...

Dec 07, 2014, 14:05 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today final data from its Phase 2 comparator-controlled study evaluating the incidence of...

Dec 05, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives Prestigious SCRIP Lifetime Achievement Award

 Stanley T. Crooke, Ph.D., M.D., founder, CEO and chairman of the board of directors of Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), has been...

Dec 03, 2014, 17:05 ET
Isis Pharmaceuticals, Inc.

ISIS-APOCIII Rx Phase 2 Study in Patients With Familial Chylomicronemia Published in the New England Journal of Medicine

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that data from a Phase 2 study of ISIS-APOCIIIRx in patients with familial...

Nov 25, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Children With Spinal Muscular Atrophy

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the initiation of a pivotal Phase 3 study evaluating ISIS-SMNRx in approximately 120...

Nov 20, 2014, 16:47 ET
Isis Pharmaceuticals, Inc.

ISIS-STAT3 Rx and ISIS-AR Rx Data Presented by AstraZeneca at European Cancer Symposium

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that data from two drugs in its anti-cancer franchise will be presented by...

Nov 18, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals to Host Webcast to Discuss ISIS-FXI Rx Data Presented at the ASH Annual Meeting

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Monday, December 8, 2014 at 9:00 a.m. Eastern...

Nov 14, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals to Present at Upcoming Investor Conferences

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview...

Nov 13, 2014, 03:01 ET
Isis Pharmaceuticals, Inc.

AstraZeneca and Isis Pharmaceuticals to Co-Develop Targeted Oligonucleotide Delivery Methods

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and AstraZeneca today announced a strategic alliance to discover and develop novel delivery methods...

Nov 12, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Prices Offering of $425 Million of 1.00% Convertible Senior Notes

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the pricing of its offering of $425.0 million aggregate principal amount of...

Nov 10, 2014, 16:03 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Announces Proposed Offering of $425 Million of Convertible Senior Notes

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it intends to offer, subject to market and other considerations, $425.0 million...

Nov 07, 2014, 08:30 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2014

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today reported a pro forma net operating loss (NOL) of $13.4 million and $34.9 million for the three...

Nov 06, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen Idec for Advancement of ISIS-BIIB3 Rx

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $10 million milestone payment from Biogen Idec related to the...

Nov 05, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Earns $7.5 Million Milestone Payment From AstraZeneca

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $7.5 million milestone payment, the first of two milestone...

Nov 03, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Earns $5 Million in Milestone Payment From GSK for Advancement of ISIS-GSK5 Rx

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $5 million milestone payment from GSK related to the designation of...

Oct 31, 2014, 07:00 ET
Isis Pharmaceuticals, Inc

Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:   What: Isis Pharmaceuticals' Third Quarter 2014...

Oct 30, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at...

Oct 10, 2014, 04:30 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals Reports Data From ISIS-SMN Rx Phase 2 Studies in Infants and Children With Spinal Muscular Atrophy

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today provided an update on its ongoing open-label Phase 2 clinical studies of ISIS-SMNRx in infants...

Oct 09, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals Earns $18 Million From GSK for Advancing ISIS-TTR Rx

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned an $18 million milestone payment from GlaxoSmithKline (GSK)...

Oct 02, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals to Host Webcast to Discuss ISIS-SMN Rx Results Presented at the World Muscle Society Congress

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Webcast and conference call to provide an update on...